Hill-Rom (NYSE:HRC) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Friday.

A number of other brokerages have also weighed in on HRC. KeyCorp reissued a “buy” rating and set a $89.00 price objective (up from $82.00) on shares of Hill-Rom in a report on Sunday, November 5th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $92.00 price target on shares of Hill-Rom in a report on Wednesday. Zacks Investment Research raised shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a report on Friday, October 27th. Needham & Company LLC lowered their price target on shares of Hill-Rom from $93.00 to $90.00 and set a “buy” rating on the stock in a report on Monday, November 6th. Finally, BidaskClub raised shares of Hill-Rom from a “sell” rating to a “hold” rating in a report on Sunday, August 6th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $89.57.

Shares of Hill-Rom (HRC) opened at $84.22 on Friday. The firm has a market cap of $5,550.00, a price-to-earnings ratio of 21.74, a PEG ratio of 1.78 and a beta of 1.19. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55. Hill-Rom has a 1-year low of $52.94 and a 1-year high of $85.25.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings data on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. The firm had revenue of $738.30 million for the quarter, compared to analyst estimates of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 earnings per share. analysts predict that Hill-Rom will post 4.26 EPS for the current fiscal year.

In other Hill-Rom news, SVP Andreas G. Frank sold 6,870 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $77.48, for a total value of $532,287.60. Following the sale, the senior vice president now directly owns 16,701 shares of the company’s stock, valued at $1,293,993.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Andreas G. Frank sold 3,940 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total transaction of $306,689.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares of the company’s stock, valued at approximately $1,300,005.84. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

Several institutional investors have recently modified their holdings of HRC. Seven Eight Capital LP acquired a new position in shares of Hill-Rom in the second quarter worth about $127,000. Acrospire Investment Management LLC raised its position in shares of Hill-Rom by 43.4% in the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock worth $158,000 after acquiring an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Hill-Rom by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock worth $175,000 after acquiring an additional 204 shares during the period. Citigroup Inc. raised its position in shares of Hill-Rom by 21.1% in the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after acquiring an additional 433 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its position in shares of Hill-Rom by 101.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock worth $204,000 after acquiring an additional 1,367 shares during the period. Institutional investors and hedge funds own 82.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/valuengine-lowers-hill-rom-hrc-to-hold/1738229.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.